IOVA
NASD Iovance Biotherapeutics Inc$14.69 ↑ +0.07 (+0.48%) Trading Up from the previous close of $14.62
- YTD change
- +438.10%
- vs 20-day SMA
- +23.32%
- vs 200-day SMA
- +193.25%
Price ranges
Price & Performance
+11.16 (+322.54%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 72.9% away from all-time highs of $54.21
- IOVA is up 438% since the beginning of the year
- IOVA is up 600% over the past 12 months
- IOVA is up 71% over the past 1 month
- 22% of all IOVA investors are betting against IOVA
IOVA reads very good: price sits above both the 20- and 200-day averages, the 12-month move is +583.2%.
- Previous minute
- +$0.00
- Last hour
- +$0.06
- Last 5 days
- +3.34%
- vs 8-day SMA
- +5.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
